Results for the substance cabotegravir

Cabotegravir is a medication used for the treatment of human immunodeficiency virus (HIV-1) infection in adults, in combination with rilpivirine. It is an integrase inhibitor that blocks the integration of viral DNA into the host cell genome, thereby preventing viral replication. Cabotegravir is available as long-acting injections, allowing for monthly or biannual administration, providing an alternative to daily oral treatments.

The medication is administered intramuscularly, according to a schedule determined by a doctor. Before initiating injectable treatment, patients may undergo an oral lead-in phase to assess tolerability.

Common side effects include injection site reactions, fever, fatigue, headache, and nausea. In rare cases, severe allergic reactions or elevated liver enzyme levels may occur.

Cabotegravir is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, it is important for patients to adhere to the administration schedule to maintain effective viral suppression.